	US 12,215,172 B2
	Bio-responsive adhesive antibody delivery platform for immunotherapy and preparation method thereof
Kye Il Joo, Daegu (KR); Hyung Joon Cha, Gyeongsangbuk-do (KR); and Yeon Su Jeong, Gyeongsangbuk-do (KR)
Assigned to POSTECH ACADEMY-INDUSTRY FOUNDATION, Pohang-si (KR)
Filed by Postech Academy-Industry Foundation, Gyeongsangbuk-do (KR)
Filed on Oct. 7, 2020, as Appl. No. 17/065,368.
Claims priority of application No. 10-2019-0127048 (KR), filed on Oct. 14, 2019.
Prior Publication US 2021/0139608 A1, May 13, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/44 (2006.01); A61K 45/00 (2006.01)

CPC C07K 16/44 (2013.01) [A61K 45/00 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)]

12 Claims

1. A mussel adhesive protein (MAP)-antibody (MAP-Ab) conjugate comprising a MAP and an anti-cancer antibody,

wherein the MAP is conjugated to the N-terminus of a peptide;

wherein the anti-cancer antibody is conjugated to the C-terminus of the peptide;

wherein the peptide is cleavable by a matrix metalloproteinase-2 (MMP2);

wherein the peptide has the amino acid sequence set forth in SEQ ID NO: 12,

wherein the anti-cancer antibody inhibits a surface protein of a cancer cell;

wherein when the MAP-Ab conjugate is exposed to an MMP2, the anti-cancer antibody is released therefrom; and

wherein the amino acid sequence of the MAP is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEO ID NO: 4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO: 10, SEQ ID NO: 11, and any combination thereof.